Aelix raises EUR 11.5M in series A

HIV vaccine developer Aelix Therapeutics S.L. (Barcelona, Spain) raised EUR 11.5 million ($12.5 million) in a series A round led by Ysios Capital. The Johnson & Johnson Innovation-JJDC venture arm of Johnson & Johnson (NYSE:JNJ) and Caixa Capital Risc also participated.

Aelix is a spinout of HIVACAT, a Catalan HIV vaccine project. Co-founder and CEO Jordi Naval told BioCentury that Aelix expects to begin a Phase I trial by 3Q16 of its lead candidate, an HTI immunogen developed as a therapeutic vaccine. Naval said Aelix expects the funds to last through completion of a Phase II trial in 2019. ...